Head of chemo firm takes leave of absence

Updated The head of the Hamilton-based company at the centre of an investigation into watered-down chemotherapy medication has taken an extended leave of absence.

That development comes hours after word the province is appointing an independent third party to find out how the drugs were given to more than 1100 patients at five hospitals in Ontario and New Brunswick. Melissa Raftis has this update: